Division of Vascular and Interventional Radiology, Department of Radiology, Tisch Hospital, New York University Langone Medical Center, HE-221, 560 First Avenue, New York, NY 10016, USA.
J Vasc Interv Radiol. 2009 Nov;20(11):1464-9. doi: 10.1016/j.jvir.2009.07.035.
To evaluate the single-incision technique for the placement of subcutaneous chest ports. Advantages, technical success, and complications were assessed.
From March 2007 through May 2008, 161 consecutive chest ports were placed with a modified single-incision technique and sonographic and fluoroscopic guidance via the right internal jugular vein (IJV; n = 130), right external jugular vein (n = 1), right subclavian vein (n = 1), or left IJV (n = 28). The primary indication was for long-term chemotherapy; all patients had malignancy.
All single-incision chest port insertions were technically successful. Ports were placed in patients 19 months to 93 years of age (mean, 56.3 y), with a mean follow-up of 203.6 device-days per patient and a total of 32,779 catheter access days. No procedure-related complications, pocket hematomas, venous thromboses, or pneumothoraces were observed. Minor delayed complications occurred in three patients. Premature catheter removal was required for two patients (1.2%; 0.006 per 100 catheter-days). One port was removed less than 30 days after implantation for infection of the pocket (0.61%; 0.003 per 100 catheter-days). Another catheter was removed because of patient dissatisfaction and unconfirmed concerns with arrhythmia (0.61%; 0.003 per 100 catheter-days). One minor superficial wound infection was successfully treated with oral antibiotics, with the port kept in place.
Use of a single-incision technique for chest port implantation in adult and pediatric oncology patients is feasible. This may be the preferred method of subcutaneous port placement, as it has a very low complication rate and a high success rate. Prospective evaluation is needed to compare it versus the conventional two-incision technique.
评估经皮单一切口技术在皮下植入式输液港中的应用。评估其优势、技术成功率和并发症。
2007 年 3 月至 2008 年 5 月,通过改良的经皮单一切口技术,在超声和透视引导下,经右侧颈内静脉(IJV;n = 130)、右侧颈外静脉(n = 1)、右侧锁骨下静脉(n = 1)或左侧 IJV(n = 28)连续置入 161 例皮下输液港。主要适应证为长期化疗;所有患者均患有恶性肿瘤。
所有单一切口输液港植入均获得技术成功。植入患者年龄 19 个月至 93 岁(平均 56.3 岁),平均随访 203.6 天/例,共 32779 天/例导管接入。未观察到与手术相关的并发症、囊袋血肿、静脉血栓形成或气胸。3 例患者发生轻微迟发性并发症。2 例患者(1.2%;0.006/100 导管天)因导管提前拔出,1 例(0.61%;0.003/100 导管天)因植入后囊袋感染而拔出,1 例(0.61%;0.003/100 导管天)因患者不满和未证实心律失常而拔出。另 1 例轻微浅表伤口感染经口服抗生素治疗后成功,保留了输液港。
在成人和儿科肿瘤患者中使用经皮单一切口技术植入输液港是可行的。这可能是皮下置管的首选方法,因为其并发症发生率低,成功率高。需要前瞻性评估以比较其与传统的两切口技术。